Burns Lucy, Teesson Maree, O'Neill Katy
National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia.
Addiction. 2005 Jun;100(6):787-96. doi: 10.1111/j.1360-0443.2005.001069.x.
This study examines the impact of comorbid Diagnostic and Statistical Manual version IV (DSM-IV) anxiety and/or depression on out-patient treatment for alcohol problems.
A prospective correlational design.
Seventy-one clients seeking alcohol out-patient treatment at two treatment sites were interviewed at commencement of a treatment episode for alcohol problems and reinterviewed using the same measures 3 months later. Comorbid DSM-IV anxiety and/or depression were measured by the Composite International Diagnostic Interview (CIDI), a comprehensive interview developed by the World Health Organization to assess current and life-time prevalence of mental disorders. Outcome measures included standardized measures of disability [the short form (SF)-12 Mental Health Summary Score and the number of days taken out of role] and the average amount of alcohol consumed. Clients were also asked to rate their satisfaction with the services received.
Participants with comorbid DSM-IV anxiety and/or depressive disorders were more disabled and drank more heavily than those without these comorbid disorders at entry to treatment. At 3-month follow-up both groups of participants (i.e. those with and without DSM-IV comorbid anxiety and/or depression) were significantly less disabled and also drank significantly less alcohol on an average drinking occasion than at baseline. Despite this, the comorbid group remained more disabled and drank more heavily than the non-comorbid group at follow-up.
Further research is needed to determine the most appropriate model of care for alcohol treatment seekers with comorbid DSM-IV anxiety and/or depression.
本研究探讨共病的《精神疾病诊断与统计手册》第四版(DSM-IV)焦虑症和/或抑郁症对酒精问题门诊治疗的影响。
前瞻性相关性设计。
在两个治疗地点寻求酒精问题门诊治疗的71名患者在酒精问题治疗疗程开始时接受了访谈,并在3个月后使用相同的测量方法再次进行访谈。共病的DSM-IV焦虑症和/或抑郁症通过综合国际诊断访谈(CIDI)进行测量,CIDI是世界卫生组织开发的一种全面访谈,用于评估精神障碍的当前和终生患病率。结果测量包括残疾的标准化测量[简表(SF)-12心理健康总结评分和脱离角色的天数]以及平均饮酒量。还要求患者对所接受服务的满意度进行评分。
在开始治疗时,患有共病的DSM-IV焦虑症和/或抑郁症的参与者比没有这些共病的参与者残疾程度更高,饮酒量也更大。在3个月的随访中,两组参与者(即患有和未患有DSM-IV共病焦虑症和/或抑郁症的参与者)的残疾程度均显著降低,并且在平均饮酒场合的饮酒量也比基线时显著减少。尽管如此,在随访时,共病组的残疾程度仍然比非共病组更高,饮酒量也更大。
需要进一步研究以确定针对患有共病的DSM-IV焦虑症和/或抑郁症的酒精治疗寻求者最合适的护理模式。